The latest shared research on Johnson and Johnson
Webinar: What Is The Outlook for the Pharma Top 10
Reserve a free place at our webinar to explore the challenges and opportunities facing the top 10 pharma companies: In response to the popularity of our recent focus on leading pharma companies, we are pleased to present this exclusive roundtable discussion, hosted by a panel of experts from the industry's leading research providers. This webinar presentation, only available to members of the PharmaShare community, will explore the latest trends within the evolving company landscape, including: Recent company performances that have shaped the competitive landscape and the strategies that have proven to be most effective in driving growth. The outlook for leading companies through ...
Rheumatologists Perceive More Patients are Taking Simponi than Cimzia
Simponi (golimumab) is a fully human monoclonal antibody against tumore necrosis factor (TNF)-alpha for the potential treatment of rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, asthma, and ulcerative colitis. In RA, Simponi is a second-generation TNF-inhibitor following Johnson & Johnson/Merck & Co.'s Remicade, and patients will be able to administer the therapy either by subcutaneous (SC) injection or intravenous (IV) infusion. While the SC formulation has launched across many major market regions, the IV formulation is still in Phase III, as of December 2010, having faced some developmental setbacks. Centocor Ortho Biotech (a subsidiary of Johnson & Johnson) and Merck & ...
J&J’s Invega Approved to Treat Schizophrenia in Adolescents
Ortho-McNeil-Janssen Pharmaceuticals, part of Johnson & Johnson, won US approval of extended-release Invega (paliperidone), an atypical antipsychotic, as a treatment for schizophrenia in adolescents 12 to 17 years. The drug was first approved in the US in December 2006 to treat adults with schizophrenia, a complex, chronic brain disorder that causes a variety of symptoms, including hearing voices, having fixed false beliefs or delusions, disorganized thinking and unusual behaviors. The disorder, which can begin during adolescence or in early adulthood, affects about 1% of adults, although the prevalence of schizophrenia in adolescents is not known, but it is estimated to be ...
J&J to land Synthes for $20bn?
Johnson & Johnson is negotiating a takeover bid for orthopedic specialist Synthes in an effort to diversify its healthcare business and strengthen its presence in the orthopedic trauma market. The news, confirmed by West Chester, Pennsylvania-headquartered Synthes, comes three months after rumors of J&J making an alleged bid for another orthopedic player, Smith & Nephew, hit the headlines ( www.clinica.co.uk, 10 January 2011). The rumoured price tag for Synthes is $20 billion, according to reports in the Wall Street Journal on 16 April. This would make it J&J's biggest acquisition to date, and one of the biggest medtech takeovers in recent ...
A Look At Risperdal Consta (risperidone long-acting injection; Johnson & Johnson) in the Treatment of Schizophrenia
Drug overview In April 2007, the US Food and Drug Administration (FDA) approved Risperdal Consta (risperidone long-acting injection; Johnson & Johnson) for the treatment of schizophrenia. Risperdal Consta became the first long-acting intramuscular (depot) atypical antipsychotic to secure approval. It was approved in Japan in April 2009 and is now approved in more than 85 countries and launched in 60 for the treatment of schizophrenia (Risperdal Consta Approved in Japan, 2009, www.medicalnewstoday.com). The drug was developed using Alkermes Medisorb technology to deliver and maintain therapeutic medication levels in the body. It is dosed every 2 weeks and this long-acting property is ...
Positioning of Remicade Relative to Simponi in Leading Indication RA
J&J’s Remicade (infliximab) is a chimeric humanized monoclonal antibody targeting tumor necrosis factor (TNF) alpha, and is indicated for multiple autoimmune diseases including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriasis, ankylosing spondylitis, and psoriatic arthritis. The product was originally developed by Centocor Ortho Biotech (a subsidiary of J&J), which has exclusive marketing rights to the drug in the US, while Merck & Co. has exclusive marketing rights throughout Europe, Russia and Turkey. Merck & Co. gained full rights to Remicade after its takeover of Schering-Plough in November 2009. Mitsubishi Tanabe Pharma markets the product in Japan and the rest of ...
Can Johnson & Johnson’s Protease Inhibitor Program Deliver a 1-2 Punch to Hepatitis C?
Ranking at 8th position in the 2010 Scrip 100 “top pharma companies” in sales in 2009, Johnson & Johnson has long cultivated breadth in the healthcare industry through its numerous acquisitions, mergers and the formation of new companies. Its acquisition in 2002 of Tibotec, now a division of Janssen Pharmaceutica and a member of the Johnson & Johnson family of companies, and its alliance with Vertex has positioned Johnson & Johnson strongly in the antiviral arena for treatment of hepatitis C infection. For patients with chronic hepatitis C, the current standard of care is peginterferon and ribavirin, which is inadequate for ...
AD/PD 2011: Alzheimer’s companies showcase new data for marketed brands
Datamonitor recently attended the 10th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2011) in Barcelona, Spain, held over March 9-13, 2011. Below are the highlights of the conference's coverage of currently marketed treatments for both diseases. Forest, Lundbeck, and Johnson & Johnson were all present to promote their Alzheimer's disease drugs Despite the lack of approved therapies in Alzheimer's disease, three of the main players presented positive data to reinforce their positions in the market place. Firstly, Forest presented three posters of its N-methyl-D-aspartic acid (NMDA) receptor antagonist Namenda (memantine). In a time-to-event analysis, the drug performed well compared to placebo, ...
